Literature DB >> 8894068

Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.

P D Harvey1, M Davidson, L White, R S Keefe, J Hirschowitz, R C Mohs, K L Davis.   

Abstract

There has been little investigation of the effect of neuroleptic medication on the structure of symptoms in schizophrenia. In this study, 135 male schizophrenic patients were rated with the Brief Psychiatric Rating Scale (BPRS) after 4 weeks of treatment with typical neuroleptic medication and after 2 weeks free of neuroleptics, with the order of assessment varying across patients. Confirmatory factor analyses (CFA) found that there were no differences in symptom structure across medication status and no differences in the structure of symptoms in treatment responders and nonresponders. The typical 5-factor BPRS model fit the data poorly and the fit improved considerably through deletion of items measuring symptoms not associated with schizophrenia, suggesting that some of the symptoms that contribute to a total BPRS score may be adding primarily error variance. Although the sample size in this study is limited, the results suggest that using total BPRS scores to measure severity of schizophrenic symptoms should be reconsidered.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8894068     DOI: 10.1016/0006-3223(95)00486-6

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  6 in total

1.  Antipsychotics and amotivation.

Authors:  Gagan Fervaha; Hiroyoshi Takeuchi; Jimmy Lee; George Foussias; Paul J Fletcher; Ofer Agid; Gary Remington
Journal:  Neuropsychopharmacology       Date:  2015-01-08       Impact factor: 7.853

2.  The dimensions of clinical and cognitive change in schizophrenia: evidence for independence of improvements.

Authors:  Philip D Harvey; Michael F Green; Christopher Bowie; Antony Loebel
Journal:  Psychopharmacology (Berl)       Date:  2006-06-17       Impact factor: 4.530

3.  Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2/3 receptor occupancy study.

Authors:  Gagan Fervaha; Fernando Caravaggio; David C Mamo; Benoit H Mulsant; Bruce G Pollock; Shinichiro Nakajima; Philip Gerretsen; Tarek K Rajji; Wanna Mar; Yusuke Iwata; Eric Plitman; Jun Ku Chung; Gary Remington; Ariel Graff-Guerrero
Journal:  Psychopharmacology (Berl)       Date:  2016-08-24       Impact factor: 4.530

4.  Effects of sample size and distributional assumptions on competing models of the factor structure of the PANSS and BPRS.

Authors:  Stephen J Tueller; Kiersten L Johnson; Kevin J Grimm; Sarah L Desmarais; Brian G Sellers; Richard A Van Dorn
Journal:  Int J Methods Psychiatr Res       Date:  2016-12-02       Impact factor: 4.035

5.  Executive functions and cognitive deficits in schizophrenia: comparisons between probands, parents and controls in India.

Authors:  T Bhatia; K Garg; M Pogue-Geile; V L Nimgaonkar; S N Deshpande
Journal:  J Postgrad Med       Date:  2009 Jan-Mar       Impact factor: 1.476

6.  Neurocognitive abnormalities during comprehension of real-world goal-directed behaviors in schizophrenia.

Authors:  Tatiana Sitnikova; Donald Goff; Gina R Kuperberg
Journal:  J Abnorm Psychol       Date:  2009-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.